AI Summary & Key Takeaways
AI InsightConclusion: All these results showed that IFN-γ, TNF-α, IL-23, IL-17 and OPN levels increase both in lesion and serum in psoriasis patients, however, further investigation should be made in order to assess their role in the immünopathogenesis of psoriasis and their relationship with the disease and comorbidities. (Turkderm 2013; 47: 142-7)
📌 3 Key Takeaways
Abstract
Background and Design: The IL23/Th17 axis is an exciting new pathway in the pathogenesis of psoriasis. Osteopontin (OPN) is a recently defined phosphorylated acidic glycoprotein which has an effect on psoriasis, especially over Th1/Th17 cells. We aimed to understand the role of OPN and Th1/Th17 pathway in the immünopathogenesis of psoriasis, to assess its relationship with disease severity and to introduce the potential target molecules for therapeutic intervention in psoriatic patients. Materials and Methods: Our study included 34 psoriatic patients. Seventeen patients were treated with corticosteroid/calsiporiol in topical treatment group and 17 patients were treated with methotrexate in the systemic treatment group. OPN and TNF-α, IFN-g, IL-23, and IL-17 levels were evaluated in serum and skin samples. The results were compared between topical and systemic treatment groups, before and after treatment. Results: There was no significant difference between the treatment groups in terms of pretreatment OPN, TNF-α, IFN-GAMA, IL-23, and IL-17 levels in serum and skin samples in psoriatic patients (p>0.05). There was no correlation of severity of psoriasis with serum cytokin levels and OPN. IFN-γ and IL-17 levels were significantly decreased after treatment in both patient groups (p0.025). The posttreatment serum OPN levels were statistically significantly decreased in systemic treatment group, whereas OPN levels were decreased in skin samples in topical treatment group after treatment. There was no statistically significant relationship of the increase in OPN, TNF-α, IFN-GAMA, IL-23, IL-17, and levels with the accompanied comorbidities. Conclusion: All these results showed that IFN-γ, TNF-α, IL-23, IL-17 and OPN levels increase both in lesion and serum in psoriasis patients, however, further investigation should be made in order to assess their role in the immünopathogenesis of psoriasis and their relationship with the disease and comorbidities. (Turkderm 2013; 47: 142-7)
Özet
Amaç: IL23/Th17 aksı psoriasis patogenezinde heyacan uyandıran yeni bir yolaktır. Osteopontin Th1/Th17 yolağı üstünden psoriasisde etki gösteren yeni tanımlanan fosforile glikoasidik glikoproteindir. Biz de çalışmamızda serum ve deri örneklerinde OPN, IFN-γ, TNF-α, IL-12, IL-23, IL-17 düzeylerini değerlendirerek, psoriasis immünpatogenezinde OPN, Th1/Th17 yolağının rolünün anlaşılması, hastalık şiddeti ile ilişkisinin değerlendirilmesini ve tedaviye yönelik araştırmalar için hedef moleküllerin ortaya konulmasını amaçladık. Gereç ve Yöntem: Çalışmamıza topikal kortikosteroid/kalsipotriol tedavisi alan 17 ve sistemik olarak metotreksat alan 17 olmak üzere toplam 34 psoriasis hastası dahil edilmiştir. OPN ve IFN-γ, TNF-α, IL-23, IL-17 düzeyleri serumda ve deri örneklerinde değerlendirilmiştir. Sonuçlar tedavi öncesi ve sonrasında topikal ve sistemik tedavi grupları arasında karşılaştırılmıştır. Bulgular: Psoriasis hastalarında tedavi öncesinde gruplar arasında serum ve deri örneklerinde OPN, IFN-γ, TNF-α, IL-23, IL-17, düzeyleri açısından istatiksel olarak anlamlı fark saptanmamıştır (p>0,05). Psoriasis şiddeti ile serum sitokin düzeyleri ve OPN arasında anlamlı korelasyon bulunmamıştır. Tedavi sonrasında deri örneklerinde IFN-γ ve IL-17 düzeylerinde istatistiksel olarak anlamlı düşüş gözlenmiştir (p0,025). Tedavi sonrasında topikal tedavi grubunda deri örneklerinde, sistemik tedavi grubunda ise serum örneklerinde OPN düzeyinde istatistiksel olarak anlamlı düşüş görülmüştür (p